1Cameron NE,Eaton SE,Cotter MA,et al.Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.Diabetologia,2001,44:1973-1988.
3Ziegler D.Therapy with antioxidants in human diabetic neuropathy.J Neurochem,2003,85(Suppl 2):15.
4Takigawa T,Yasuda H,Terada M,et al.Increases in K+ conductance and Ca 2+influx under high glucose with suppressed Na+/K+-pump activity in rat myelinated nerve fibers.Neuroreport,2000,11:2547-2551.
5Shimizu H,Ohtani KI,Tsuchiya T,et al.Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese type 2 diabetic (T2DM) patients.Diabetes Nutr Metab,2000,13:75-79.
6Asano T,Saito Y,Kawakami M,et al.Fidarestat (SNK-860),a potent aldose reductase inhibitor,normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.J Diabetes Complications,2002,16:133-138.
7Cameron NE,Cotter MA.Vascular changes in animal models of diabetic neuropathy.J Neurochem,2003,85(Suppl 2):14.
8Hounsom L,Corder R,Patel J,et al.Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy.Diabetologia,2001,44:424-428.
9Purves T,Middlemas A,Agthong S,et al.A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.FASEB J,2001,15:2508-2514.
10Valls CJ,Povedano M,Montero J,et al.Diabetic polyneuropathy,axonal or demyelinating.Electromyogr Clin Neurophysiol,2002,42:3-6.
